Antiinflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice

S. Crikis, X. M. Zhang, S. Dezfouli, K. M. Dwyer, L. M. Murray-Segal, E. Salvaris, C. Selan, S. C. Robson, H. H. Nandurkar, P. J. Cowan, A. J. F. D'Apice

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

Thrombomodulin (TBM) is an important vascular anticoagulant that has species specific effects. When expressed as a transgene in pigs, human (h)TBM might abrogate thrombotic manifestations of acute vascular rejection (AVR) that occur when GalT-KO and/or complement regulator transgenic pig organs are transplanted to primates. hTBM transgenic mice were generated and characterized to determine whether this approach might show benefit without the development of deleterious hemorrhagic phenotypes. hTBM mice are viable and are not subject to spontaneous hemorrhage, although they have a prolonged bleeding time. They are resistant to intravenous collagen-induced pulmonary thromboembolism, stasis-induced venous thrombosis and pulmonary embolism. Cardiac grafts from hTBM mice to rats treated with cyclosporine in a model of AVR have prolonged survival compared to controls. hTBM reduced the inflammatory reaction in the vein wall in the stasis-induced thrombosis and mouse-to-rat xenograft models and reduced HMGB1 levels in LPS-treated mice. These results indicate that transgenic expression of hTBM has anticoagulant and antiinflammatory effects that are graft-protective in murine models. ? 2010 The American Society of Transplantation and the American Society of Transplant Surgeons.
Original languageEnglish
Pages (from-to)242 - 250
Number of pages9
JournalAmerican Journal of Transplantation
Volume10
Issue number2
DOIs
Publication statusPublished - Feb 2010
Externally publishedYes

Cite this